Table 1.

Overview of primers used for quantitative PCR assays in the study.

Target	Forward sequence	Reverse sequence
ACTB	ACCACACCTTCTACAATGAG	TAGCACAGCCTGGATAGC
CGA	AACCCATTCTTCTCCCAGCC	GTGGACTCTGAGGTGACGTT
ELF3	GGCCGATGACTTGGTACTGA	CAGCTCCTCAAGGGCACAAT
ELF5	TAAATCGGAAGCCCTGGCAA	ACTAACCTTCGGTCAACCCG
EPCAM	GAATGGCAAAGTATGAGAAGGCTGA	TCCCACGCACACACATTTGTAA
GAPDH	ACCCACTCCTCCACCTTTGAC	TCCACCACCCTGTTGCTGTAG
GATA3	CTCATTAAGCCCAAGCGAAG	GCATTCCTCCTCCAGAGTGT
HLA-A generic	TGGAGGAGGAAYAGCTCAGATA	CAAGGCAGCTGTCTCACAC
HLA-B generic	CCTAGCAGTTGTGGTCATC	AGCCCTGGGCACGGTCG
HLA-C generic	TGTCCTGGYTGTCCTAGCT	TGTCTCAGGCTTTACAAGYGA
HLA-C*01	CACAGACTGACCGAGTGAG	CCCCAGGTCGCAGCCAC
HLA-C*02/12	CCGCGGGTATGACCAGTC	CTCCAGGTAGGCTCTCCA
HLA-C*02/17	CGAGTGAACCTGCGGAAA	GAGCCACTCCACGCACTC
HLA-C*03	CACAGACTGACCGAGTGAG	AGCGTCTCCTTCCCATTCTT
HLA-C*04/18	CGAGTGAACCTGCGGAAA	GCCCCAGGTCGCAGCCAA
HLA-C*05	CGAGTGAACCTGCGGAAA	CGCGCGCTGCAGCGTCTT
HLA-C*06	TACTACAACCAGAGCGAGGA	GGTCGCAGCCATACATCCA
HLA-C*07	TACTACAACCAGAGCGAGGA	ACGGGCCGCCTCCA
HLA-C*07:03	TACTACAACCAGAGCGAGGA	GAGCCACTCCACGCACAG
HLA-C*08	ACGACACGCAGTTCGTGCA	GCGCAGGTTCCGCAGGC
HLA-C*14	CCACTCCATGAGGTATTTCTC	GGTCGCAGCCAAACATCCA
HLA-C*16	CCGCGGGTATGACCAGTC	CCCTCCAGGTAGGCTCTCT
HLA-C*18	AGTCCGAGAGGGGAGCCC	GCCCCAGGTCGCAGCCAA
HLA-DRB1 generic	ACAGTGGAATGGAGAGCACGG	CCAGAGTGTCCTTTCTGATTCCT
HLA-G generic	GACAGCGACTCGGCGT	GTGTTCCGTGTCTCCTCT
HLA-G1	ATGCTGCAGCGCGCGGACC	TGGGCAGGGAAGACTGCTTCCA
HLA-G2	ACCAGAGCGAGGCCAACCC	GGCAGGGAAGACTGCTTCCA
HLA-G3	AACCAGAGCGAGGCCAAGCAG	AGCTCCCTCCTTTTCAATCTGAG
ITGA1	TCAATGACTTTCAGCGGCCC	ACCTCTCCCAACTGGACACT
ITGA5	GGCTTCAACTTAGACGCGGA	GGCCGGTAAAACTCCACTGA
ITGA6	GAGCTTTTGTGATGGGCGATT	CTCTCCACCAACTTCATAAGGC
TEAD4	TGGACAAGCCCATCGACAAT	TGCCTGGTCCTTTAGCTTGG
TFAP2C	TGGACGAGGTGCAGAATGTC	TCAGTGGGGTTCATTACGGC